Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLNO Soleno Therapeutics

Market Closed 12-12 16:00:00 EST

52.00

+2.51

+5.07%

盘后52.00

+0.000.00%

18:29 EST

High52.79	Low49.10	Vol1.45M
Open49.80	D1 Closing49.49	Amplitude7.46%
Mkt Cap2.79B	Tradable Cap2.33B	Total Shares53.71M
T/O73.74M	T/O Rate3.23%	Tradable Shares44.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":52,"timestamp":1765573200000,"preClose":49.49,"halted":0,"volume":1447103,"hourTrading":{"tag":"盘后","latestPrice":52,"preClose":52,"latestTime":"18:29 EST","volume":15868,"amount":825126.2492,"timestamp":1765582164851},"delay":0,"floatShares":44870900,"shares":53710025,"eps":-1.618287,"marketStatus":"Market Closed","change":2.51,"latestTime":"12-12 16:00:00 EST","open":49.8,"high":52.79,"low":49.1,"amount":73739134.708449,"amplitude":0.074561,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.618287,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":49.49,"preHourTrading":{"tag":"盘前","latestPrice":49.81,"preClose":49.49,"latestTime":"09:12 EST","volume":524,"amount":26016.398784,"timestamp":1765548741523},"postHourTrading":{"tag":"盘后","latestPrice":52,"preClose":52,"latestTime":"18:29 EST","volume":15868,"amount":825126.2492,"timestamp":1765582164851},"volumeRatio":0.953535486861639,"impliedVol":0.6156,"impliedVolPercentile":0.372},"requestUrl":"/m/hq/s/SLNO/tweets","defaultTab":"tweets","newsList":[{"id":"2588046610","title":"Soleno Therapeutics (SLNO) Valuation Check After Wolfe’s Bullish Call Challenges Short-Seller Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046610","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046610?lang=en_us&edition=fundamental","pubTime":"2025-12-04 15:17","pubTimestamp":1764832634,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) is back on traders’ radar after Wolfe Research launched coverage with a bullish stance, pushing back against short seller driven worries about its lead drug and recent launch stumbles.\nSee our latest analysis for Soleno Therapeutics.\nThe upbeat Wolfe call has helped steady sentiment after a bruising few months. The 1 day share price return of 5.41% has partially offset a 30 day share price return of minus 22.74%, while the three year total shareholder return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-check-after-wolfes-bullis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/soleno-therapeutics-slno-valuation-check-after-wolfes-bullis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO","DCF","BK4139","BK4112"],"gpt_icon":1},{"id":"2588702125","title":"Press Release: Soleno Therapeutics Announces the Passing of Board Member William G. Harris","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588702125?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795900,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Dec. 03, 2025  -- Soleno Therapeutics, Inc.  , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today regrets to announce the passing of William G. \"Bill\" Harris, who served as a valued member of Soleno's Board of Directors since June 2014. Mr. Harris also served as Chairman of the Audit Committee.This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms su","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SLNO","BK4585","BK4099","BK4604","TM","BK4555","03160","BK4139"],"gpt_icon":0},{"id":"2588408580","title":"How Does Wolfe Research’s Support Shape Soleno Therapeutics’ (SLNO) Credibility Amid Heightened Scrutiny?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588408580","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588408580?lang=en_us&edition=fundamental","pubTime":"2025-12-02 09:12","pubTimestamp":1764637966,"startTime":"0","endTime":"0","summary":"Wolfe Research recently initiated coverage on Soleno Therapeutics, providing a positive outlook for ViCAT XR after concerns were raised over its safety and commercial prospects.\nThis coverage comes in the wake of both a short seller report and ongoing legal investigations, reflecting heightened scrutiny and contrasting expert perspectives for investors.\nWe’ll explore how Wolfe Research’s assessment of ViCAT XR’s insurance access and patient growth prospects shapes the company’s investment...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-does-wolfe-researchs-support-shape-soleno-therapeutics-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-does-wolfe-researchs-support-shape-soleno-therapeutics-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2584397284","title":"Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Business Officer Kevin Norrett","url":"https://stock-news.laohu8.com/highlight/detail?id=2584397284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584397284?lang=en_us&edition=fundamental","pubTime":"2025-11-20 07:49","pubTimestamp":1763596149,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Kevin Norrett, Chief Business Officer of the company, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL8xK02x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2584446921","title":"Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2584446921","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584446921?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:19","pubTimestamp":1763572769,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Soleno Therapeutics Inc ::*SOLENO THERAPEUTICS ANNOUNCES ENTRY INTO $100 MILLION ACCELERATED SHARE REPURCHASE AGREEMENT  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 11-NOV-202512:00:00.397 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2yrk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2584895499","title":"Soleno Therapeutics Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2584895499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584895499?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:55","pubTimestamp":1763484900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SLNO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 11:55 ET (16:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"gpt_icon":0},{"id":"2584954619","title":"Soleno Therapeutics Unveils Corporate Presentation Highlighting VYKAT XR Launch for Prader-Willi Syndrome Hyperphagia","url":"https://stock-news.laohu8.com/highlight/detail?id=2584954619","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584954619?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:46","pubTimestamp":1763484412,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has announced the launch of VYKAT XR, the first FDA-approved treatment for hyperphagia in adults and pediatric patients aged four years and older with Prader-Willi syndrome . The company highlighted a defined U.S. market opportunity of over $5 billion and a target patient population of approximately 10,000 individuals. VYKAT XR is protected by multiple layers of granted and pending patents extending into the mid-2030s, and Soleno reported achieving profitability and positive cash flow in the third quarter of 2025. Clinical trial data presented showed sustained reductions in hyperphagia, as measured by HQ-CT total scores, over multiple years in open-label and controlled studies. The company also emphasized the significant burden PWS places on patients, caregivers, and healthcare systems, including higher rates of hospital stays and increased caregiver stress. You can access the full presentation through the link below.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL1H4phG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2584956157","title":"How Investors May Respond To Soleno Therapeutics (SLNO) Legal Scrutiny After Accelerated Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2584956157","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584956157?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:22","pubTimestamp":1763464947,"startTime":"0","endTime":"0","summary":"Earlier this month, Soleno Therapeutics announced a US$100 million accelerated share repurchase agreement with Jefferies LLC after reporting a net income of US$26.01 million for the third quarter of 2025, reversing a significant loss from the prior year.\nThis announcement came amid increasing scrutiny from law firms investigating Soleno’s disclosures about its VYKAT XR drug following concerns around trial outcomes and adverse events.\nWe'll explore how the emergence of legal investigations...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-investors-may-respond-to-soleno-therapeutics-slno-legal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/how-investors-may-respond-to-soleno-therapeutics-slno-legal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4211","BK4139","SLNO"],"gpt_icon":0},{"id":"2583589695","title":"Soleno Therapeutics Files Initial Beneficial Ownership Statement for Chief Development Officer Manher Joshi","url":"https://stock-news.laohu8.com/highlight/detail?id=2583589695","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583589695?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:19","pubTimestamp":1762985985,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Manher Joshi as the beneficial owner, serving in the role of Chief Development Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7hqhqT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2582367235","title":"Soleno Therapeutics Shares Rise 5.5% After $100 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2582367235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582367235?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:39","pubTimestamp":1762871988,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nL4N3WN11A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2582362696","title":"BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, Soleno","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362696?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:08","pubTimestamp":1762870114,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Nebius, Estee Lauder, SolenoEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nL6N3WN0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EL","PSKY","NVD2.UK","SG9999014914.USD","NVDL","3NVD.UK","CLSK","ROL","BYND","NVD","SLNO","LU1720051017.SGD","VSAT","NVDA","NEM","REAL","LU2326559502.SGD","RKLB","CDE","AI","VOR","NVDY","CRWV","YTRA","LU1066051498.USD","BBAI","NVDD","LU0234572021.USD","IE00B775H168.HKD","NVDU","RGTI","NVDS","SE","NBIS","NVD3.UK","HNRG","NVIW.SI","SUNC","LU0175139822.USD","SNVD.UK","VG","NVDS.UK","2NVD.UK","ASTS","BK4183","LU0203201768.USD","HL","LU1069344957.HKD","LU2265009873.SGD","NVDX"],"gpt_icon":0},{"id":"2582368361","title":"Soleno Therapeutics Shares Rise 8.4% Premarket After Co Announces Entry Into $100 Mln Accelerated Share Repurchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582368361?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:09","pubTimestamp":1762866586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nL4N3WN0X8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2582169366","title":"Soleno Therapeutics Signs $100 Million Accelerated Share Repurchase Deal; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2582169366","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582169366?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:24","pubTimestamp":1762863869,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics  said Tuesday it has signed an accelerated share repurchase agreement for $100 million of its common shares.Under the agreement with Jefferies, Soleno said it will make an initial payment of $100 million with an initial delivery of about 1.5 million shares based on the company's closing stock price Monday.The company expects to complete the share repurchase agreement in Q1.Soleno shares were up 9.4% in recent premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"1150638039","title":"Stock Track | Soleno Therapeutics Soars 5.70% Pre-market on $100 Million Share Repurchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1150638039","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150638039?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:04","pubTimestamp":1762862658,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) saw its stock price surge 5.70% in pre-market trading on Tuesday, following a significant corporate announcement. The biopharmaceutical company revealed its entry into a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0},{"id":"2582365916","title":"Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365916","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365916?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:00","pubTimestamp":1762862401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUA3PGZ5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"1141640344","title":"Stock Track | Soleno Therapeutics Plummets 5.44% Pre-Market on New Financial Risk Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=1141640344","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141640344?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:31","pubTimestamp":1762443109,"startTime":"0","endTime":"0","summary":"Shares of Soleno Therapeutics (SLNO) took a sharp dive in pre-market trading on Thursday, plummeting 5.44% following the company's disclosure of new financial risks. The biopharmaceutical firm, known...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLNO"],"gpt_icon":0},{"id":"2581603714","title":"Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2581603714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581603714?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:01","pubTimestamp":1762408909,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) has disclosed a new risk, in the Accounting & Financial Operations category. Soleno Therapeutics faces significant busin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-financial-challenges-navigating-risks-in-vykat-xr-commercialization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/soleno-therapeutics-financial-challenges-navigating-risks-in-vykat-xr-commercialization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2581777083","title":"Soleno Therapeutics falls -29.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777083","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581777083?lang=en_us&edition=fundamental","pubTime":"2025-11-06 01:05","pubTimestamp":1762362356,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics (SLNO) is down -29.0%, or -$18.49 to $45.36. Published first on TheFly – the ultimate source for real-time, market-moving break...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-falls-29-0-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/soleno-therapeutics-falls-29-0-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO","BK4139"],"gpt_icon":0},{"id":"2581772429","title":"Soleno Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581772429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581772429?lang=en_us&edition=fundamental","pubTime":"2025-11-06 00:46","pubTimestamp":1762361160,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics Inc  is currently at $45.16, down $18.70 or 29.28%. --Would be lowest close since March 11, 2025, when it closed at $44.78. --On pace for largest percent decrease since March 8, 2021, when it fell 48.7%. --Currently down five consecutive days; down 35.45% over this period. --Longest losing streak since Sept. 16, 2025, when it fell for six straight trading days. --Down 93.12% from its all-time closing high of $656.25 on March 4, 2015. --Down 20.59% from 52 weeks ago , when it closed at $56.86. --Down 48.97% from its 52-week closing high of $88.49 on July 9, 2025. --Up 6.15% from its 52-week closing low of $42.54 on Jan. 14, 2025. --Traded as low as $43.89; lowest intraday level since March 11, 2025, when it hit $43.00. --Down 31.26% at today's intraday low; largest intraday percent decrease since March 8, 2021, when it fell as much as 49.83%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"gpt_icon":0},{"id":"2581777461","title":"Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581777461?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:46","pubTimestamp":1762357577,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $123.00. Kluska covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-buy-rating-for-soleno-therapeutics-slno-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLNO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":0.0123},{"period":"1month","weight":0.0895},{"period":"3month","weight":-0.0302},{"period":"6month","weight":-0.343},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1568}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.04369},{"month":2,"riseRate":0.272727,"avgChangeRate":0.254619},{"month":3,"riseRate":0.636364,"avgChangeRate":0.007758},{"month":4,"riseRate":0.454545,"avgChangeRate":0.050237},{"month":5,"riseRate":0.545455,"avgChangeRate":0.074125},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.416667,"avgChangeRate":0.061278}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Soleno Therapeutics(SLNO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction